1 Secondary
end points included a composite of mortality, clinical ischem
2 Other secondary efficacy
end points included additional VAS items (burning/stinging, i
3 Secondary
end points included analysis of the kinetics of anti-5T4 resp
4 Secondary
end points included anatomic patency, adverse event rate, and
5 Secondary
end points included cardiac magnetic resonance-determined myo
6 Secondary
end points included change in body weight and cardiometabolic
7 Coprimary
end points included change in brachial artery flow-mediated d
8 Exploratory
end points included change in high-sensitivity C-reactive pro
9 Secondary
end points included change in QOL from baseline to week 24, c
10 Secondary
end points included changes in LV volumes, infarct size, and
11 Key secondary
end points included changes in patient-reported disease activ
12 d point was reintervention post-RV decompression; secondary
end points included circulation type at latest follow-up.
13 Secondary
end points included clinical outcomes (major adverse cardiac
14 Secondary
end points included disease-free survival and the cumulative
15 Safety
end points included hyperkalemia and changes in renal functio
16 Secondary
end points included incidence of fluid overload, duration of
17 Secondary
end points included intraoperative and postoperative complica
18 Prespecified
end points included left ventricular mass index and, in a sub
19 Primary end point was in-hospital mortality; secondary
end points included new-onset organ failure.
20 End points included nonfatal myocardial infarction and fatal
21 Secondary
end points included number of days of use of other illicit su
22 Secondary
end points included numbers of intraepithelial lymphocytes, s
23 Secondary
end points included other visual analog scale (eg, high and d
24 The primary end point was PFS; secondary
end points included overall survival (OS), objective response
25 Secondary
end points included overall survival and subgroup analyses of
26 Secondary
end points included overall survival, distant metastasis-free
27 Secondary
end points included overall survival, local and regional PFS,
28 Secondary
end points included overall survival, objective response rate
29 Secondary
end points included overall survival, PFS by HA level, and ob
30 Secondary
end points included overall survival, safety, and biomarker a
31 Secondary
end points included percentage of responders by age strata an
32 Secondary
end points included relapse-free survival (RFS) and TRM.
33 Secondary
end points included repeat revascularization and a composite
34 End points included safety (primary), objective response rate
35 Secondary
end points included safety and predictive impact of early res
36 Secondary
end points included safety, assessed as the rate and grade of
37 The secondary
end points included short-term weight loss, serum obesity-rel
38 Secondary
end points included superiority in achieving biochemical end
39 Other
end points included target lesion revascularization, thrombos
40 Secondary
end points included the clinical congestion score, dyspnea as
41 Secondary
end points included the effect on hematinic and cardiac bioma
42 Secondary
end points included the incidences of nonvertebral and hip fr
43 Secondary
end points included the objective response rate, overall surv
44 Secondary
end points included the proportion of patients with at least
45 Secondary
end points included the rate of nocturnal symptomatic hypogly
46 Secondary
end points included the restoration of hemostasis and safety
47 Secondary
end points included the time to first relapse and the average
48 The key secondary
end points included time to first SRE and skeletal morbidity
49 Secondary
end points included time to second progression or death, toxi
50 primary end point was locoregional control (LRC); secondary
end points included toxicity, compliance, response, progressi